The noninflammatory role of high mobility group box 1/toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells
出版年份 2013 全文链接
标题
The noninflammatory role of high mobility group box 1/toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells
作者
关键词
-
出版物
FASEB JOURNAL
Volume 27, Issue 12, Pages 4731-4744
出版商
FASEB
发表日期
2013-08-23
DOI
10.1096/fj.13-230201
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- SCA-1 Identifies the Tumor-Initiating Cells in Mammary Tumors of BALB-neuT Transgenic Mice
- (2015) Cristina Grange et al. NEOPLASIA
- TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence
- (2013) Ilana Chefetz et al. CELL CYCLE
- Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty
- (2012) Jeffrey A. Magee et al. CANCER CELL
- STAT3-Driven Upregulation of TLR2 Promotes Gastric Tumorigenesis Independent of Tumor Inflammation
- (2012) Hazel Tye et al. CANCER CELL
- Cancer Vaccination Drives Nanog-Dependent Evolution of Tumor Cells toward an Immune-Resistant and Stem-like Phenotype
- (2012) K. H. Noh et al. CANCER RESEARCH
- Triple Negative Breast Cancer: From Molecular Portrait to Therapeutic Intervention
- (2012) Pietro Carotenuto et al. CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION
- Gene Silencing of Toll-Like Receptor 2 Inhibits Proliferation of Human Liver Cancer Cells and Secretion of Inflammatory Cytokines
- (2012) Yuzheng Huang et al. PLoS One
- Role of TLR2-dependent inflammation in metastatic progression
- (2011) Sunhwa Kim et al. Annals of the New York Academy of Sciences
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Regulation of Cancer Stem Cells by Cytokine Networks: Attacking Cancer's Inflammatory Roots
- (2011) H. Korkaya et al. CLINICAL CANCER RESEARCH
- NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation
- (2011) C R Jeter et al. ONCOGENE
- Important aspects of Toll-like receptors, ligands and their signaling pathways
- (2010) Z. L. Chang INFLAMMATION RESEARCH
- The therapeutic promise of the cancer stem cell concept
- (2010) Natasha Y. Frank et al. JOURNAL OF CLINICAL INVESTIGATION
- Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands
- (2010) Xiaoxia Z. West et al. NATURE
- Bacteria Peptidoglycan Promoted Breast Cancer Cell Invasiveness and Adhesiveness by Targeting Toll-Like Receptor 2 in the Cancer Cells
- (2010) Wenjie Xie et al. PLoS One
- Toll-Like Receptor 2 Mediates Proliferation, Survival, NF-κB Translocation, and Cytokine mRNA Expression in LIF-Maintained Mouse Embryonic Stem Cells
- (2010) Tammi Taylor et al. STEM CELLS AND DEVELOPMENT
- Targeting the Mechanisms of Resistance to Chemotherapy and Radiotherapy with the Cancer Stem Cell Hypothesis
- (2010) Ryan Morrison et al. Journal of Oncology
- Toll-like receptor 2 mediates invasion via activating NF-κB in MDA-MB-231 breast cancer cells
- (2009) Wenjie Xie et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature
- (2009) Emmanuelle Charafe-Jauffret et al. CANCER RESEARCH
- TLR2 plays a role in the activation of human resident renal stem/progenitor cells
- (2009) Fabio Sallustio et al. FASEB JOURNAL
- Blocking TLR2 Activity Attenuates Pulmonary Metastases of Tumor
- (2009) Hong-Zhen Yang et al. PLoS One
- HMGB1: a two-headed signal regulating tumor progression and immunity
- (2008) Lara Campana et al. CURRENT OPINION IN IMMUNOLOGY
- Microbial Patterns Signaling via Toll-Like Receptors 2 and 5 Contribute to Epithelial Repair, Growth and Survival
- (2008) Renat Shaykhiev et al. PLoS One
- Isolation and Molecular Characterization of Cancer Stem Cells in MMTV-Wnt-1Murine Breast Tumors
- (2007) Robert W. Cho et al. STEM CELLS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now